Trending Topic

3d illustration of human body liver
12 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Allan A Lima Pereira, Gabriel Lenz, Tiago Biachi de Castria

Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise from the biliary epithelium of the small ducts in the periphery of the liver […]

Steven Pipe, ASH 2020 – First Results from the HOPE-B Gene Therapy Trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 23rd 2020

We had the pleasure to talk to Steven Pipe (University of Michigan, Ann Arbor, MI, USA) to discuss the use of gene therapy for the treatment of haemophilia B. The abstract ‘First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies’ (ABSTRACT NUMBER: LBA-6) was presented at the Virtual 2020 ASH Congress, 2–10 December 2020.

Questions

  1. What are the major challenges and opportunities of gene therapy for haemophilia B? (0:18)
  2. What is etranacogene dezaparvovec and how does it differ from other gene therapy candidates? (3:13)
  3. What were the aims and design of the HOPE-B study? (4:59)
  4. What have we learned from the first data from this study and what other endpoints will be assessed at 52 weeks? (6:48)

Disclosures: Steven Pipe has served as a consultant to Apcintex, Bayer, Biomarin, Catalyst Biosciences, CSL Behring, HEMA Biologics, Freeline, Novo Nordisk, Pfizer, Roche/Genentech, Sangamo Therapeutics, Sanofi, Takeda, Spark Therapeutics and uniQure.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup